Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Heron Therapeutics (HRTX) Leases (2019 - 2025)

Heron Therapeutics filings provide 9 years of Leases readings, the most recent being $708000.0 for Q3 2025.

  • On a quarterly basis, Leases fell 79.59% to $708000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $708000.0, a 79.59% decrease, with the full-year FY2024 number at $2.8 million, down 48.75% from a year prior.
  • Leases hit $708000.0 in Q3 2025 for Heron Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $15.6 million in Q1 2021 to a low of $708000.0 in Q3 2025.
  • Median Leases over the past 5 years was $6.5 million (2023), compared with a mean of $7.0 million.
  • Biggest five-year swings in Leases: fell 14.5% in 2021 and later crashed 79.59% in 2025.
  • Heron Therapeutics' Leases stood at $9.8 million in 2021, then dropped by 22.22% to $7.6 million in 2022, then dropped by 28.87% to $5.4 million in 2023, then tumbled by 48.75% to $2.8 million in 2024, then tumbled by 74.6% to $708000.0 in 2025.
  • The last three reported values for Leases were $708000.0 (Q3 2025), $1.4 million (Q2 2025), and $2.1 million (Q1 2025) per Business Quant data.